Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting

Journal of the American Academy of Dermatology

Volumn 66, Issue 1, 2012, Pages 148-152

  Kardos, Marisa ^a   Kimball, Alexa Boer ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anti tumor necrosis factor; interferon gamma release assay; latent tuberculosis; psoriasis; screening

Indexed keywords

ADALIMUMAB; BCG VACCINE; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; METHOTREXATE;

BCG VACCINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RECURRENT INFECTION; REVIEW; TUBERCULIN TEST;

EID: 83655192761     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.09.007     Document Type: Editorial

References (22)

1. Centers for Disease Control and Prevention Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010 MMWR Morb Mortal Wkly Rep 59 2010 1 28
2. Centers for Disease Control and Prevention. The difference between latent TB infection and active TB disease; March 2010. Available from: URL: http://www.cdc.gov/tb/publications/factsheets/general/LTBIandActiveTB.htm. Accessed July 18, 2011.
3. J.A. Singh, G.A. Wells, R. Christensen, E. Tanjong Ghogomu, L. Maxwell, and J.K. Macdonald Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2 2011 CD008794
4. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent N Engl J Med 345 2001 1098 1104
5. A. Lalvani, and M.A. Pareek 100 year update on diagnosis of tuberculosis infection Br Med Bull 93 2010 69 84
6. R. Diel, R. Loddenkemper, and A. Nienhaus Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a meta-analysis Chest 137 2010 952 968
7. E.Y. Kim, J.E. Lim, J.Y. Jung, J.Y. Son, K.J. Lee, and Y.W. Yoon Performance of the tuberculin skin test and interferon-gamma release assay in immunocompromised patients in a BCG-vaccinated population BMC Infect Dis 9 2009 207
8. C.M. Denkinger, K. Dheda, and M. Pai Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 17 2011 806 814
9. G. Tsiouri, G. Gaitanis, D. Kiorpelidou, A. Dionysiou, A. Efthymiou, and G. Daskalopoulos Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis Dermatology 219 2009 119 125
10. S.D. Doherty, A. Van Voorhees, M.G. Lebwohl, N.J. Korman, M. Young, and S. Hsu National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents J Am Acad Dermatol 59 2008 209 217
11. A.I. Sánchez-Moya, and E. Dauden Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients J Eur Acad Dermatol Venereol 25 2011 730 733
12. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, and E. Long Antitumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 2003 148 155 (Pubitemid 36278124)
13. Remicade (infliximab) for intravenous injection [prescribing information] 2010 Centocor Inc Malvern, PA
14. Humira (adalimumab) for subcutaneous injection [prescribing information] 2010 Abbott Biotechnology North Chicago, IL
15. Enbrel (etanercept) for subcutaneous injection [prescribing information] 2010 Immunex Corp Thousand Oaks, CA
16. R.S. Wallis, M.S. Broder, J.Y. Wong, M.E. Hanson, and D.O. Beenhouwer Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 2004 1261 1265 (Pubitemid 38608568)
17. J.J. Gomez-Reino, L. Carmona, M. Angel Descalzo Biobadaser Group Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection Arthritis Rheum 57 2007 756 761 (Pubitemid 46932080)
18. E. Laffitte, J.P. Janssens, P. Roux-Lombard, A.M. Thielen, C. Barde, and G. Marazza Tuberculosis screening in patients with psoriasis before antitumor necrosis factor therapy: comparison of an interferon-γ release assay vs tuberculin skin test Br J Dermatol 161 2009 797 800
19. M. Bocchino, A. Matarese, B. Bellofiore, P. Giacomelli, G. Santoro, and N. Balato Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment Eur J Clin Microbiol Infect Dis 27 2008 907 913
20. N. Desai, Y. Raste, N.T. Cooke, and C.C. Harland QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumor necrosis factor α therapy Br J Dermatol 158 2008 1137 1138 (Pubitemid 351521427)
21. J. Martin, C. Walsh, A. Gibbs, T. McDonnell, U. Fearon, and J. Keane Comparison of interferon {gamma} release assays and conventional screening tests before tumor necrosis factor {alpha} blockade in patients with inflammatory arthritis Ann Rheum Dis 69 2010 181 185
22. National Collaborating Centre for Chronic Conditions Tuberculosis: clinical diagnosis and management of tuberculosis and measure for its prevention and control 2008 Royal College of Physicians London